Davidson's corporate practice focuses on financing and other transactions for life science, clean technology and high-technology clients. All three industry groups cross paths frequently.
For instance, Davidson represented Amyris Inc. in its $84 million initial public offering last year to fund the Emeryville-based company's cleantech and biotechnology research.
Amyris started in 2003 to develop an anti-malaria drug, but it also turn...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In